Kirsavoglu Betul, Odabasi Ozan, Avci Ibrahim Erkut
Psychiatry, Istanbul Erenkoy Mental and Nervous Diseases Training and Research Hospital, Istanbul, Turkey.
Urology, Kocaeli University, School of Medicine, Kocaeli, Turkey.
Gen Psychiatr. 2021 Oct 12;34(5):e100586. doi: 10.1136/gpsych-2021-100586. eCollection 2021.
Solifenacin is a muscarinic receptor antagonist that has been used to treat overactive bladder since 2004. It has a great affinity for the detrusor M3 receptor, which must be stimulated for bladder muscle contraction, and demonstrates the most selective profile to the bladder of the muscarinic receptor subtypes. It is thought that urinary antimuscarinic agents, due to their passage to the central nervous system and lipophilic properties, may cause central nervous system symptoms in some rare cases. A case report of a 42-year-old male patient who had an acute psychotic attack as a result of solifenacin treatment for overactive bladder is presented in this article.
索利那新是一种毒蕈碱受体拮抗剂,自2004年以来一直用于治疗膀胱过度活动症。它对逼尿肌M3受体具有高度亲和力,而膀胱肌肉收缩必须刺激该受体,并且它对毒蕈碱受体亚型的膀胱表现出最具选择性的特征。人们认为,尿路抗毒蕈碱药物由于其进入中枢神经系统以及具有亲脂性,在某些罕见情况下可能会引起中枢神经系统症状。本文介绍了一名42岁男性患者的病例报告,该患者因使用索利那新治疗膀胱过度活动症而发生急性精神病发作。